NeuroSearch advises of prosecutions initiated agai

Announcement 17.07.2013 Reference is made to the company's previous announcement dated 25 May 2012 (announcement 14-12). NeuroSearch A/S (NEUR) advises that the company is now being prosecuted by the Danish Public Prosecutor for Special Economic and International Crimes for alleged qualified share price manipulation under Section 39, subsection 1, cf. Section 38, subsection 1, no. 1, cf. Section 94, subsection 1, second sentence, cf. Section 94, subsection 2, cf. Section 93, subsection 6 of the Danish Securities Trading Act. The Public Prosecutor requests that NeuroSearch is fined. The charges relate to an announcement issued on 3 February 2010 in which the then management of the company reported top-line results from the Phase III study with Huntexil^® for the treatment of Huntington's disease (the MermaiHD study). The data were subsequently reassessed and on 28 April 2010, the company, on its own initiative, released a corrective announcement. On the present basis, NeuroSearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter. René Schneider CEO Contact person René Schneider, CEO, telephone: +45 2911 2097 About NeuroSearch NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.